New drug combo aims to speed recovery from rare, severe drug reaction

NCT ID NCT06734884

First seen May 16, 2026 · Last updated May 23, 2026 · Updated 2 times

Summary

This study tests whether adding benralizumab (a drug that targets certain immune cells) to standard steroid treatment can help people with DRESS syndrome recover faster and spend fewer days in the hospital. DRESS is a rare, serious reaction to medications that can affect the skin and internal organs. About 96 adults with DRESS will be randomly assigned to receive either benralizumab or a placebo, along with corticosteroids, and researchers will track their hospital stay and symptom improvement over 52 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRESS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Delphine STAUMONT-SALLE

    Lille, Nord, 59000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.